Samsrita Labs Ltd vs Variman Global Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 24, 2026

Key Highlights

The Latest Trading Price of Samsrita Labs Ltd is ₹ 13.42 as of 23 Oct 15:30 . The P/E Ratio of Samsrita Labs Ltd changed from 28.5 on March 2022 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Variman Global Enterprises Ltd changed from 47.3 on March 2021 to 16.2 on March 2026 . This represents a CAGR of -16.35% over 6 years The Market Cap of Samsrita Labs Ltd changed from ₹ 64.64 crore on March 2021 to ₹ 36.08 crore on March 2026 . This represents a CAGR of -9.26% over 6 yearsThe Market Cap of Variman Global Enterprises Ltd changed from ₹ 45.14 crore on March 2021 to ₹ 53.65 crore on March 2026 . This represents a CAGR of 2.92% over 6 years The revenue of Samsrita Labs Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0.05 crore. This represent the decline of -100% The revenue of Variman Global Enterprises Ltd for the Jun '26 is ₹ 26.06 crore as compare to the Mar '26 revenue of ₹ 44.46 crore. This represent the decline of -41.39% The ebitda of Samsrita Labs Ltd for the Jun '26 is ₹ -0.31 crore as compare to the Mar '26 ebitda of ₹ -0.12 crore. This represent the growth of 158.33% The ebitda of Variman Global Enterprises Ltd for the Jun '26 is ₹ 2.57 crore as compare to the Mar '26 ebitda of ₹ 1.9 crore. This represent the growth of 35.26% The net profit of Samsrita Labs Ltd changed from ₹ -0.28 crore to ₹ -0.31 crore over 5 quarters. This represents a CAGR of 8.48% The net profit of Variman Global Enterprises Ltd changed from ₹ 0.2 crore to ₹ 1.07 crore over 9 quarters. This represents a CAGR of 110.72% The Dividend Payout of Samsrita Labs Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Variman Global Enterprises Ltd changed from 38.05 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .

About Samsrita Labs Ltd

Samsrita Labs Limited was initially established as 'Dr Habeebullah Life Sciences Limited' on January 25, 1996.
The name of the Company was changed from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited on October 13, 2022.
Company, initially focused on three different verticals called, Stem cell related Hospitals, Molecular Diagnostics and R&D in New Drug Discovery but due to other reasons, aimed to shifting into Bio-pharma activities like Trading, Exports & Imports, manufacturing of Bulk drugs, APIs, Specialty drugs, R&D etc through joint ventures or associations or mergers or by its own.
The Company is engaged into the business of research & experimental development on natural sciences and engineering, including bio pharma and hospital services also. In 2017, the Company changed its Main Objects clauses by venturing into the business of Bio-Pharma and also entered the following areas like New Drug Discovery including New Molecular Entity (NME - Pro Drug); Clinical Research Organization (CRO) related activities; Stem Cell - Lab, Research and Therapy; Research and Development in Bio-technology; Consultancy Division and Pharmacy; Academic Services like Courses / Lectures / Seminars on Biotechnology, Pharma, Stem Cell Research and therapy, Clinical Research and animal studies etc.

About Variman Global Enterprises Ltd

Variman Global Enterprises Limited was erstwhile incorporated as 'Spring fields Securities Limited' in December 1993.
Name of the Company was changed from Spring Field Securities Limited to 'Spring Fields Infraventures Limited' in 2015 and again was changed from Spring Fields Infraventures Limited to 'Variman Global Enterprises Limited' w.e.f. 16 December 2019. The Company started its commercial operations in 1993 and is a leading IT infrastructure solutions provider through software development, IT Infrastructure solutions and distributing IT Hardware to clients and partners through aggressive market development in Telangana.
It is presently engaged in distribution of HPMPS division and EATON Power Solutions.
Apart from these, Variman portfolio includes end user computing from Desktops, laptops, server and server room technologies, printing, imaging and scanning solutions, networking solutions, wireless technologies, security & firewall solutions to IT infrastructure.

FAQs for the comparison of Samsrita Labs Ltd and Variman Global Enterprises Ltd

Which company has a larger market capitalization, Samsrita Labs Ltd or Variman Global Enterprises Ltd?

Market cap of Samsrita Labs Ltd is 30 Cr while Market cap of Variman Global Enterprises Ltd is 75 Cr

What are the key factors driving the stock performance of Samsrita Labs Ltd and Variman Global Enterprises Ltd?

The stock performance of Samsrita Labs Ltd and Variman Global Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Samsrita Labs Ltd and Variman Global Enterprises Ltd?

As of October 24, 2026, the Samsrita Labs Ltd stock price is INR ₹13.42. On the other hand, Variman Global Enterprises Ltd stock price is INR ₹3.85.

How do dividend payouts of Samsrita Labs Ltd and Variman Global Enterprises Ltd compare?

To compare the dividend payouts of Samsrita Labs Ltd and Variman Global Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.